Circulating Activities During Constant Infusion of Heparin or a Low Molecular Weight Derivative (Enoxaparine): Failure to Demonstrate any Circadian Variations

Summary

We compared in six patients successively treated with an unfractionated heparin (UFH) and a low molecular weight heparin (LMWH) the variations in plasma anti-Xa activity, measured in a chromogenic assay, during a 36 h constant infusion. The values varied in a wider range during UHF infusion, but remained in the therapeutic range except once in one patient. No circadian rhythm could be demonstrated in our six patients. LMWH infusion yielded very constant anti-Xa circulating activities. In both cases, there were no significant modifications of three proteins with high heparin affinity (antithrombin III, heparin cofactor II, histidine-rich glycoprotein).

Our results suggest that the circadian rhythm of the biological activities previously observed in patients treated with constant heparin infusion using clotting method is due to other factors than heparin itself.

Keywords

Unfractionated heparin - Low molecular weight heparin - Circadian variations - Plasma heparin activity

• References

• 1 Décousus HA, Croze M, Levi FA, Jaubert JG, Perpoint BM, De Bonadona JF, Reinberg A, Queneau PM. Circadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med J 1985; 290: 341-344
• 2 Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. New Engl J Med 1986; 315: 1109-1114
• 3 Mant MJ, O’Brien B, Thong KL. Haemorrhagic complications of heparin therapy. Lancet 1977; i: 1133-1135
• 4 Wilson JE, Bynum LJ, Parkey RW. Heparin therapy in venous thromboembolism. Am J Med 1981; 70: 808-816
• 5 Rosenberg RD, Damus PS. The purification and mechanism of action of human anthb • ;nbin heparin cofactor. J Biol Chem 1973; 248: 4690-4505
• 6 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
• 7 Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983; 258: 3803-3808
• 8 Aiach M, Michaud A, Balian JL, Lefebvre M, Woler M, Fourtillan J. A new low molecular weight heparin derivative. In vitro and in vivo studies. Thromb Res 1983; 31: 611-621
• 9 Aiach M, Léon M, Michaud A, Capron L. Adaptation of synthetic peptide substrate-based assays on a discrete analyzer. Seminars in Thromb Hemostas 1983; 9: 206-216
• 10 Toulon P, Jacquot C, Capron L, Frydman MO, Vignon D, Aiach M. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis. Thromb Haemostas 1987; 57: 263-268
• 11 Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1972; 29 suppl (124) 21-37
• 12 Bingham C, Arbogast B, Guillaume GC, Lee JK, Halberg F. Inferential statistical methods for estimating and comparing cosinor parameters. Chronobiologia 1982; 9: 397-439
• 13 Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-636
• 14 Barzu T, Mohlo P, Tobelem G, Petitou M, Caen JP. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985; 845: 196-203
• 15 Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; ii: 581-584
• 16 Schved JF, Gris JC, Eledjam JJ. Circadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med J 1985; 290: 1286
• 17 Johnston KR, Wenham GA, Clapham MC. Circadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med J 1985; 290: 792
• 18 Barrowcliffe TW, Gray E, Merton RE, Dawes J, Jennings CA, Hubbard AR, Thomas DP. Anticoagulant activities of pentosan polysulphate (Hémoclar) due to release of hepatic triglyceride lipase (HTGL). Thromb Haemostas 1986; 56: 202-206
• 19 Dawes J, Prowse CV, Pepper DS. Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb Res 1986; 44: 683-693
• 20 Scully MF, Décousus HA, Ellis V, Parker C, Girard P, Kakkar VV. Measurement of heparin in plasma: Influence of inter-subject and circadian variability in heparin sensitivity according to method. Thromb Res 1987; 46: 447-455